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OBJECTIVE: High genistein doses have been reported to induce fluid accumulation in the uteri of
ovariectomised rats, although the mechanism underlying this effect remains unknown. Because genistein
binds to the oestrogen receptor and the cystic fibrosis transmembrane regulator mediates uterine fluid
secretion, we hypothesised that this genistein effect involves both the oestrogen receptor and cystic fibrosis
transmembrane regulator.
METHODS: Ovariectomised adult female Sprague-Dawley rats were treated with 25, 50, or 100 mg/kg/day
genistein for three consecutive days with and without the ER antagonist ICI 182780. One day after the final
drug injection, the animals were humanely sacrificed, and the uteri were removed for histology and cystic
fibrosis transmembrane regulator mRNA and protein expression analysis using real-time polymerase chain
reaction and Western blotting, respectively. The cystic fibrosis transmembrane regulator protein distribution
was analysed visually by immunohistochemistry.
RESULTS: The histological analysis revealed an increase in the circumference of the uterine lumen with
increasing doses of genistein, which was suggestive of fluid accumulation. Moreover, genistein stimulated a
dose-dependent increase in the expression of cystic fibrosis transmembrane regulator protein and mRNA, and
high-intensity cystic fibrosis transmembrane regulator immunostaining was observed at the apical membrane
of the luminal epithelium following 50 and 100 mg/kg/day genistein treatment. The genistein-induced increase
in uterine luminal circumference and cystic fibrosis transmembrane regulator expression was antagonised by
treatment with ICI 182780.
CONCLUSION: Genistein-induced luminal fluid accumulation in ovariectomised rats’ uteri involves the oestrogen
receptor and up-regulation of cystic fibrosis transmembrane regulator expression, and these findings reveal the
mechanism underlying the effect of this compound on changes in fluid volume in the uterus after menopause.
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Genistein, a phyto-oestrogen, is capable of binding to
oestrogen receptor (ER)-a and b, which are expressed in the
uterus (1). This compound has also been reported to induce
morphological changes (2), luminal fluid secretion (3) and
proliferation of the endometrium, as evidenced by the
increased expression of proliferative markers (3,4) in the
uteri of ovariectomised adult rats. These genistein-mediated
effects may have various implications on the female
reproductive system. For example, genistein-induced
changes may help to restore some uterine functions and
reduce uterine atrophy after menopause (5). At high doses,
however, genistein may produce harmful effects because it
can stimulate the development of endometrial hyperplasia
(3,6). There is also evidence that genistein can affect female
fertility by interfering with the normal development of the
reproductive system (7,8) and the normal pattern of the
reproductive cycle (7).
The reported effects of genistein on fluid secretion may
affect the volume of fluid in the uterus. Under conditions in
which a low amount of fluid is present, such as in
menopause (9), genistein may help to restore the uterine
fluid volume. Although changes in morphology and fluid
secretion have been reported in rodent uteri, genistein has
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been shown to have no significant effect on restoring normal
endometrial morphology in humans (10) and primates (11)
after menopause. The presence of fluid within the uterine
cavity in the post-menopausal period is typically associated
with endometrial pathology, although increased fluid
accumulation has also been observed in healthy post-
menopausal women (9). Therefore, the function of fluid in
the uterus post-menopause remains unknown. In females of
reproductive age, a normal amount of uterine fluid is
important to sustain fertility (12), as any interference with
the fluid volume can result in infertility (13). Before
menopause, uterine fluid volume regulation is under the
control of sex steroids such as oestrogen (E2) and progester-
one (P4) (14).
The cystic fibrosis transmembrane regulator (CFTR), a
cAMP-dependent chloride channel, plays an important role
in mediating uterine fluid secretion (15,16). CFTR mutations
lead to cystic fibrosis, a disease associated with defective
Cl- and fluid secretion (17). CFTR has been reported to be
expressed at the apical membrane of the endometrial
epithelium (14), and its function is dependent on cyclic
AMP (cAMP) (18). In addition to secreting fluid and Cl-,
CFTR has also been reported to participate in cAMP-
dependent HCO3
- secretion (19). CFTR expression is under
the influence of sex-steroids; this protein is down-regulated
by P4 and up-regulated by E2, during the proestrus and
estrus stages of the oestrous cycle in rats (15). The effect of
genistein on uterine CFTR expression is unknown, although
this compound has been reported to affect CFTR expression
in the intestine (20,21), kidney (22), airways (23), and
epididymis (24).
Genistein is widely consumed as a supplement to prevent
or alleviate menopause-related symptoms such as hot
flashes, night sweats, and headaches (25). In addition, this
compound has also been shown to assist in overcoming
post-menopausal-related complications such as osteoporo-
sis (26) and cardiovascular diseases such as hypertension
and ischaemic heart disease (27). Despite its wide use, the
effect of genistein on the post-menopausal uterus remains
poorly characterised. However, limited data indicate that
this compound can cause fluid accumulation in the uteri of
ovariectomised rats (3). Because the underlying mechanism
is unknown, the present study investigated the involvement
of the ER and CFTR in regulating this genistein-mediated
effect. This study is of clinical significance because the
presence of fluid in the uterine cavity of post-menopausal
women could be due to high genistein consumption in
addition to other factors known to cause fluid accumulation
in the uterus during this period.
& METHODS
Animal preparation and hormone treatment
Three-month-old adult female Sprague-Dawley (SD) rats
weighing approximately 225 g were housed in a clean and
well-ventilated animal room with standardised housing
conditions (lights on for 12 h from 06:00 h to 18:00 h; room
temperature of 24 C˚; 5-6 animals per cage). Post-weaning,
the animals were provided free access to a soy-free diet
(Gold-Coin Pellets) and water free of dissolved endocrine-
disrupting chemicals (EDCs). All procedures were
approved by the Faculty of Medicine, Animal Care and
Use Committee, University of Malaya, under ethics number
FIS/01/12/2008 (NFK). Genistein (G-6055) was purchased
from LC Laboratories (Woburn, MA, USA) at greater than
99% purity; this compound is a crystalline powder with a
light yellowish colour.
Bilateral ovariectomy was performed under isoflurane
anaesthesia at least ten days prior to drug treatment to
eliminate the effect of endogenous sex steroids (14). After
surgery, the animals were given intramuscular injections of
0.1 ml Kombitrim antibiotic to prevent post-surgical wound
infection. The animals were divided into eight groups (n= 6
per group). Group 1 was treated for three days with peanut
oil (vehicle); groups 2 to 7 received subcutaneous injections
of genistein at doses of 25, 50, and 100 mg/kg/day for three
consecutive days with and without the ER antagonist ICI
182780 at 100 mg/kg/day; and group 8 received ICI 182780
only at 100 mg/kg/day. The drugs were dissolved in peanut
oil and were then administered via subcutaneous injection
behind the scruff of the neck.
Uterine morphological analyses
At the end of the 3-day period, the rats were sacrificed via
anaesthetic overdose followed by cervical dislocation 24 h
after the last drug treatment. The right uterine horns were
immediately harvested and fixed in 4% paraformaldehyde
(PFD) at 4 C˚ for 4 to 5 h. A standardised region of the
uterine horn for all animals (mid-portion) was processed
using an automated tissue processing machine (Leica,
Germany). Tissues were then embedded in paraffin wax
using conventional methods, and sections with a thickness
of 5 mm were prepared and mounted onto glass slides. The
sections were then stained with haematoxylin and eosin
(H&E) and visualised under a light microscope (Olympus,
Japan). The circumference of the uterine lumen was
measured using the NIS-Elements AR program. All images
were captured using a Nikon Eclipse 80i camera that was
attached to the light microscope.
Quantification of CFTR mRNA expression by
real-time PCR
Immediately after the animals were sacrificed, the uteri
were removed and placed into RNAlater solution (Ambion,
USA), which maintains RNA integrity prior to extraction.
In this study, the absolute quantification method, which
correlates the PCR signal to a standard curve, was used to
determine the copy number of RNA (28). Absolute
quantification provides the exact copy number (29) and
can be used to compare various treatment groups. In brief,
the protocol for PCR included the following steps. First,
total RNA was freshly isolated from rat uteri using the
RNeasy Plus Mini Kit (Qiagen, USA). The total RNA
concentration in the tissue samples was then determined
using a Nanodrop (Fisher-Scientific). Reverse transcription
into cDNA was performed using a High-capacity RNA-to-
cDNA Kit (Applied Biosystems, USA). TaqmanH real-time
PCR was used to evaluate gene expression, with B-actin
and GAPDH serving as endogenous controls. The PCR
program consisted of 2 min at 50 C˚ for UNG activity, 20 s
at 95 C˚ for activation of the ampliTaq gold DNA
polymerase, 1 min of denaturation at 95 C˚, 20 s for
annealing, and extension at 60 C˚ for 1 min. Denaturing
and annealing were performed for 40 cycles. All TaqMan
assays were purchased from Applied Biosystem, USA.
Control reactions included amplifications performed on
samples identically prepared with no reverse transcriptase
(-RT) or no added substrate (water control). The CFTR
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Primer was obtained from Roche (USA) with id number
Rn014559. Each reaction was performed in duplicate on
RNA isolated from three separate animals. The average
crossover point (CT) was determined using Roche software
and was then converted into copy number per ng of total
RNA by comparison to the standard curve. For absolute
quantification, standard cDNA (Roche, USA) was diluted
to different concentrations, and a standard curve was
generated. Quantitative PCR was then performed as
described above.
Quantification of CFTR protein expression by
Western blotting
Snap-frozen uterine tissues were homogenised using a
sonicator with PRO-PREP (Intron) extraction solution in the
presence of protease inhibitors. Total cell protein was
obtained by centrifugation at 13,000 g for 15 min at 4 C˚.
After determination of the protein concentration, an equal
amount of protein was loaded onto a 12% SDS-PAGE gel.
The protein was then transferred onto a PVDF membrane
and incubated in 5% BSA for 90 min. The blot was then
exposed to the primary antibody at a 1:1,000 dilution. After
incubation with a CFTR goat polyclonal antibody obtained
from Santa Cruz, USA, the blot was incubated with HRP-
conjugated secondary antibody and was finally visualised
using Optic 4C (Bio RAD). B-actin (abCam, UK) was used as
a loading control. Photos of the blots were captured, and the
density of each band was determined using Image J
software. The ratio of each band/b-actin was determined
and was considered the expression level of each of the target
proteins.
Localisation of CFTR protein distribution by
immunohistochemistry (IHC)
Immunohistochemistry was performed to examine the
CFTR protein distribution in the uterus. Uterine paraffin
blocks from the various treatment groups were sectioned
into 5 mm thick sections and mounted onto glass slides. The
tissue sections were incubated in 10% H2O2 in methanol to
quench the activity of endogenous peroxidase and were
then incubated overnight with primary antibody (rat
polyclonal IgG) against CFTR at a 1:100 dilution at 4 C˚ in
a humidified chamber. The tissues were then incubated
with secondary antibody, i.e., biotinylated rabbit anti-rat
IgG (Amersham, UK), at 1:500 for 1 h at room temperature
followed by tertiary antibody, i.e., streptavidin-horseradish
peroxidase (Amersham, UK), at 1:500 for 1 h at room
temperature. The sites of antibody binding were visualised
using DAB (diaminobenzidine HCl), which provided a
dark brown stain. The sections were then counterstained
with haematoxylin for nuclear staining.
Evaluation of immunostaining
The relative intensity of the immunoreactions at the
luminal and glandular epithelium was evaluated and
graded blindly by three independent observers using a
light microscope (Olympus, Japan) at 40X and 100X
magnifications. The staining intensity was estimated semi-
quantitatively on a scale of 0–3+ (+++) as follows: 2, no
detectable stain; 2/+, faint; +, moderate; ++, strong and +++,
very intense staining, as previously described (30).
Statistical analyses
The results are expressed as the mean ¡ SEM, with n
indicating the number of rats. Comparisons between groups
were performed using one-way ANOVA. P-values ,0.05
were considered statistically significant. Data assist v3 was
used to analyse the real-time PCR (qPCR) results.
& RESULTS
Effect of genistein treatment on uterine luminal
circumference
Figure 1 shows images of uterine sections from ovar-
iectomised rats pre-treated with genistein at various doses
with and without the presence of the ER antagonist ICI
182780, whereas Table 1 presents the circumference of the
uterine lumen from these treatment groups. Treatment with
25, 50, and 100 mg/kg/day genistein resulted in 1.19-, 3.94-,
and 4.76-fold increases in uterine circumference, respec-
tively, compared with the control. Administration of ICI
182780 significantly reduced the genistein-related increase
in uterine luminal circumference. In particular, ICI 182780
administration resulted in 1.1-, 3.06-, and 2.17-fold decreases
in uterine circumference in the groups receiving 25, 50, and
100 mg/kg/day genistein, respectively. ICI 182780 treat-
ment alone did not cause any significant changes in uterine
circumference compared with the control treatment.
CFTR mRNA expression analysis by real-time PCR
(qPCR)
Based on the CT values obtained for each sample, CFTR
mRNA expression was quantified using the absolute
quantification method. Absolute and relative quantifications
have been shown to produce comparable results (31).
Figure 2(a) shows the standard curve generated using
standard cDNA. As shown in Figure 2(b), the absolute
CFTR mRNA expression was determined according to the
standard curve from CT values obtained in each treatment
group. CFTR mRNA expression was markedly increased
following 25, 50, and 100 mg/kg/day genistein treatment,
and these levels were 6.8-, 13.5-, and 26.75-fold greater,
respectively, than the control. Administration of ICI 182780
resulted in a significant inhibition of mRNA expression in
all groups receiving different doses of genistein.
CFTR protein expression analysis by Western
blotting
As shown in Figure 3, the expression of CFTR protein was
increased with increasing doses of genistein. The ratio of
CFTR/B-actin was 2.92- and 3.35-fold higher in the groups
treated with 50 and 100 mg/kg/day genistein, respectively,
compared with the group receiving 25 mg/kg/day genis-
tein treatment. Meanwhile, ICI 182780 administration led to
a significant decrease in genistein-induced CFTR protein
expression in all treatment groups.
Analysis of CFTR protein distribution by IHC
Figure 4 shows images of the endometrium at 206
magnification and the luminal epithelium at 1006magni-
fication, whereas Table 2 presents a semi-quantitative
analysis of the staining intensity of CFTR in various
treatment groups with and without ICI 182780. Our findings
indicated that the intensity of immunostaining was highest
following treatment with 50 and 100 mg/kg/day genistein,
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predominantly at the luminal and glandular epithelium,
and these intensity values were decreased following ICI
182780 administration. CFTR immunostaining was highest
at the apical membrane of the luminal epithelium following
treatment with 50 and 100 mg/kg/day genistein. Mild to
moderate staining could be observed following treatment
with 25 mg/kg/day genistein, which was also reduced
following ICI 182780 administration. Incubation with non-
immune peptide resulted in no staining (negative control).
& DISCUSSION
To the best of our knowledge, this study was the first to
report the mechanism underlying genistein-induced fluid
accumulation in the uteri of ovariectomised rats. Our study
confirmed the previous observation that genistein at high
doses (50 and 100 mg/kg/day) leads to a significant
increase in fluid volume in the uteri of ovariectomised rats
(3). Although the significance of this effect is unknown, it
could help to restore fluid in the uterus after menopause.
Because high-dose genistein has also been reported to cause
an increase in the thickness of the endometrium and
myometrium in ovariectomised rats (3), this compound
may therefore be used to block uterine atrophy resulting
from a lack of oestrogen. In other studies involving
ovariectomised rats, high-dose genistein (100 mg/kg/day)
was reported to increase bone mineral density (BMD) (32)
and partially regress atrophied mammary glands (33). In
humans, consumption of a genistein-rich diet, including
approximately 50 mg/day of this compound, by women in
the post-menopausal period has been reported to reduce the
incidence of vasomotor episodes such as hot flashes (34).
Genistein supplementation has also been found to decrease
the total cholesterol (35) and low density lipoprotein (LDL)
(36) levels and to reduce the risk for breast cancer
development (37) in women after menopause.
Our findings revealed that genistein-induced fluid accu-
mulation in the uteri of ovariectomised rats involves the ER,
as evidenced from the antagonising effect of ICI 182780. The
effect of genistein on ER expression in the uterus has been
previously reported. Administration of selective soy extract
(SSE) containing genistein at 50 and 100 mg/kg/day to
ovariectomised rats was found to enhance the expression of
ER-b in the uterine stroma. This increase in ER-b expression
was shown to negatively modulate the expression of ER-a in
the luminal epithelia (38). Down-regulation of ER-a has also
been reported in the uteri of intact non-ovariectomised rats
receiving chronic genistein treatment (39), suggesting that
this effect may be due to the up-regulation of ER-b
expression by genistein. In view of these findings, we
speculated that the effect of genistein as observed in our
study may be mediated via ER-b, although further studies
are needed to confirm this hypothesis.
In humans, the presence of fluid within the uterine cavity
of post-menopausal women has been associated with
Table 1 - Measurement of the circumference of the
uterine lumen in ovariectomised rats treated with peanut
oil (control) and different doses of genistein (25, 50 and
100 mg/kg/day) with and without ICI 182780. The values
represent the mean ¡ SEM, with n=6 per treatment
group. The circumference was increased with increasing
doses of genistein. Administration of ICI 182780 reduced
the uterine circumference in all genistein-treated groups.
Uterine luminal circumference (mm)
Control With ICI 182780
Vehicle 1,693¡78.98 1,622.97¡69.11
25G 2,019.97¡60.13 *,{ 1,837.95¡75.44
50G 6,674.11¡100.32 *,{ 2,182¡99.18
100G 8,062.84¡125.76 *,{ 3,721¡102.49
Figure 1 - Representative images of uterine sections from ovariectomised SD rats treated with (A) peanut oil (control), (B) 25G (25 mg/
kg/day genistein), (C) 25G (25 mg/kg/day genistein) + ICI 182780, (D) 50G (50 mg/kg/day genistein), (E) 50G (50 mg/kg/day genistein + ICI
182780), (F) 100G (100 mg/kg/day genistein), (G) 100G (100 mg/kg/day genistein) + ICI 182780, or (H) ICI 182780 (100 mg/kg/day) only for
3 consecutive days. There was a clear increase in the luminal circumference following treatment with 50 and 100 mg/kg/day genistein,
although these changes were antagonised by treatment with ICI 182780. Sections were stained with H&E, and the magnification is X4. L
indicates the uterine lumen. (G-genistein), n= 6 per treatment group.
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endometrial malignancy (40) and cervical stenosis (41). In
most cases, however, there is no obvious relationship
between the neoplastic lesions and the amount of fluid
within the uterus after menopause (42). In women who have
no pathological lesions either in the uterus or cervix,
increased uterine fluid amount after menopause is almost
always associated with advancing age (43) and the co-
existence of medical conditions such as diabetes and
hypertension (9). The association between the use of
hormone replacement therapy (HRT), i.e., oestrogen or
selective ER modulators (SERMs), and post-menopausal
uterine fluid accumulation remains unknown. Because our
study found that genistein induced fluid accumulation in
the uteri of ovariectomised rats, it is possible that this
compound may lead to increased fluid accumulation in the
uterus during the post-menopausal period. High-dose
genistein intake should therefore be considered as one of
the causes for increased fluid levels in the uteri of post-
menopausal women.
Our findings also revealed that CFTR is involved in
mediating the genistein-induced increase in the fluid
amount in ovariectomised rats’ uteri. In particular, we
found that the expression of CFTR mRNA and protein was
markedly increased following treatment with 50 and
100 mg/kg/day genistein. Up-regulation of CFTR mRNA
and protein expression was dependent on the ER, suggest-
ing that this effect was mediated via a genomic pathway.
Under the effect of genistein, CFTR was expressed mainly at
the apical membrane of the luminal epithelium, which
suggests that it may participate in fluid, Cl-, and HCO3-
secretion into the uterine lumen. The importance of CFTR in
mediating uterine fluid secretion was demonstrated by
Navis et al. (44), in which deletion of the CFTR gene was
found to inhibit luminal fluid secretion. Our hypothesis that
CFTR is involved in uterine fluid secretion is also supported
by the observation that a marked increase in uterine CFTR
expression occurs in diseases related to excessive fluid
accumulation in the uterus, such as hydrosalpinx (45). Apart
from the uterus, CFTR has been reported to mediate fluid
secretion in the small intestine (46), submucosal glands (47),
and salivary glands (48). Therefore, it is likely that the
observed increase in fluid accumulation within the uterine
lumen was due to genistein-induced CFTR up-regulation. In
addition to mediating fluid secretion, CFTR has also been
Figure 2 - Representative images of the uterine glandular and luminal epithelium under 20X magnification and the luminal epithelium
under 100X magnification (in the upper right-hand corner) from ovariectomised SD rats treated with (A) control (vehicle-treated) (B)
25G (25 mg/kg/day genistein), (C) 25G (25 mg/kg/day genistein) + ICI 182780, (D) 50G (50 mg/kg/day), (E) 50G (50 mg/kg/day genistein)
+ ICI 182780, (F) 100G (100 mg/kg/day genistein), (G) 100G (100 mg/kg/day genistein) + ICI 182780, or (H) ICI 182780 (100 mg/kg/day) only
for 3 consecutive days or (I) incubation with a non-immune peptide. There was a clear increase in the intensity of immunostaining in
the group treated with 100 mg/kg/day genistein. L- uterine lumen, Gl– uterine gland, G-genistein. Sections were stained with H&E for
nuclear staining; n =6 per treatment group.
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reported to be involved in Cl- and HCO3
- secretion in the
uterus (49), small intestine (20), and airways (50). As
genistein has been reported to induce CFTR-mediated Cl-
secretion in the small intestine (20) and jejunum (51), it is
likely that this compound may also stimulate Cl- secretion in
the uterus via CFTR.
This study investigated the acute effect of genistein on
fluid accumulation and CFTR protein and mRNA expres-
sion in the uterus of ovariectomised rats. Three days of
genistein treatment was sufficient to cause an increase in
CFTR expression in the uterus. A similar duration of
genistein treatment in ovariectomised rats was also found
to induce changes in the morphology of the uterus and
vagina (52) and affect the expression of several other
proteins, including proliferative cell nuclear antigen
(PCNA) (2,3) and complement C3 (53) in the uterus and
blood, respectively. In this study, the route of genistein
administration could represent the limiting factor for
extrapolating these findings to humans. In humans, this
compound is usually consumed orally as a dietary supple-
ment or as a component of the diet. Moreover, the level of
genistein in the blood is expected to be higher following
subcutaneous administration compared with oral adminis-
tration, as orally administered genistein is metabolised by
the gut flora to 5-hydroxy-equol (54). In addition, oral
genistein administration also undergoes metabolism in the
liver (55). Thus, the lack of uterotopic responses observed in
humans following oral genistein consumption (10) is likely
due to low plasma bioavailability as the consequence of
these first-pass effects.
In conclusion, genistein-induced fluid accumulation in
the uteri of ovariectomised rats was shown to involve the
Figure 3 - (a) Standard curve obtained from cDNA dilution. The y axis represents the absolute nuclear DNA copy number, and the x axis
represents the CT value. The linear regression equation was given by y=1E+06e-0.34x, R2 = 0.989. (b) CFTR mRNA expression evaluated by
real-time PCR. The absolute copy number (per 1 ng mRNA used for real-time PCR) was calculated from the standard curve (a). The
expression of CFTR mRNA was 26 times higher following treatment with 100 mg/kg/day genistein compared with the control. The
absolute copy number obtained from each sample represents the mean of four assays with the standard deviation. C = control, ICI =
ICI 182780, 25G=25 mg/kg/day genistein, 25G (25 mg/kg/day genistein) + ICI 182780, 50G=50 mg/kg/day genistein, 50G (50 mg/kg/day
genistein) + ICI 182780, 100G=100 mg/kg/day genistein, 100G (100 mg/kg/day genistein) + ICI 182780.
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ER and CFTR, and these findings reveal the underlying
effect of this compound on the uterus after menopause.
Although the significance of this effect is unknown, this
compound may help to restore fluid within the uterine
cavity and inhibit uterine atrophy. Finally, high-dose
genistein consumption, rather than the presence of malig-
nancy, should be considered a potential cause for fluid in
the uteri of post-menopausal women.
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100G=100 mg/kg/day genistein.
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